Search Results - "Hoogi, Shiran"

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function by Hoogi, Shiran, Eisenberg, Vasyl, Mayer, Shimrit, Shamul, Astar, Barliya, Tilda, Cohen, Cyrille J.

    Published in Journal for immunotherapy of cancer (09-09-2019)
    “…BackgroundTumors can employ different mechanisms to evade immune surveillance and function. Overexpression of co-inhibitory ligands that bind to checkpoint…”
    Get full text
    Journal Article
  2. 2

    Targeting Multiple Tumors Using T-Cells Engineered to Express a Natural Cytotoxicity Receptor 2-Based Chimeric Receptor by Eisenberg, Vasyl, Shamalov, Katerina, Meir, Shimrit, Hoogi, Shiran, Sarkar, Rhitajit, Pinker, Shirel, Markel, Gal, Porgador, Angel, Cohen, Cyrille J

    Published in Frontiers in immunology (29-09-2017)
    “…Recent developments in cancer treatment are demonstrating the increasing and powerful potential of immunotherapeutic strategies. In this regard, the adoptive…”
    Get full text
    Journal Article
  3. 3

    Genetically engineering glycolysis in T cells increases their antitumor function by Toledano Zur, Raphaëlle, Atar, Orna, Barliya, Tilda, Hoogi, Shiran, Abramovich, Ifat, Gottlieb, Eyal, Ron-Harel, Noga, Cohen, Cyrille J

    Published in Journal for immunotherapy of cancer (04-07-2024)
    “…BackgroundT cells play a central role in the antitumor response. However, they often face numerous hurdles in the tumor microenvironment, including the…”
    Get full text
    Journal Article
  4. 4

    T-cells “à la CAR-T(e)” – Genetically engineering T-cell response against cancer by Eisenberg, Vasyl, Hoogi, Shiran, Shamul, Astar, Barliya, Tilda, Cohen, Cyrille J.

    Published in Advanced drug delivery reviews (15-02-2019)
    “…The last decade will be remembered as the dawn of the immunotherapy era during which we have witnessed the approval by regulatory agencies of genetically…”
    Get full text
    Journal Article
  5. 5